Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Concluded with an LOI
Manufacturer:
EMD Serono Canada, a division of EMD Inc.
Indication:
Urothelial carcinoma (UC), first-line maintenance treatment of patients with locally advanced or metastatic whose disease has not progressed with first-line platinum-based induction chemotherapy
Last updated:
December 15, 2021
Status:
Concluded without agreement
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Migraine, Chronic
Last updated:
December 13, 2021
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Acute myeloid leukemia (AML) newly diagnosed in patients who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy (in combination with azacitidine)
Last updated:
December 6, 2021
Status:
Concluded with an LOI
Manufacturer:
Teva Canada Ltd.
Indication:
Prevention of Migraine in Adults
Last updated:
December 3, 2021
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), relapsed or refractory, in adult patients who are not eligible for autologous stem cell transplant & have received at least one prior therapy (In combination with bendamustine & rituximab)
Last updated:
December 1, 2021
Duobrii (Halobetasol propionate and tazarotene)
Status:
Concluded with an LOI
Manufacturer:
Bausch Health, Canada Inc.
Indication:
Psoriasis, moderate to severe plaque
Last updated:
November 30, 2021
Status:
Negotiations were not pursued
Manufacturer:
Novo Nordisk Canada Inc.
Indication:
Chronic weight management
Last updated:
November 22, 2021
Status:
Concluded with an LOI
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Severe Hypoglycemia
Last updated:
November 22, 2021
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT
Last updated:
November 18, 2021
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT
Last updated:
November 18, 2021